View Older Stories View More Recent Stories
-
Hackett Group, Inc. (HCKT) Shows Strength in North America; Roth Capital Raises Price Target to $18
-
Canadian Solar (CSIQ) Capacity Expansion Continues Accelerating; Roth Affirms at 'Buy'
-
Roth Trims PT on Galena (GALE) Following Q3 Results, Plans to Spin Commercial Assets
-
Roth Capital Cuts Price Target on Exar Corp. (EXAR) Following In-Line 2Q Results
-
Curis (CRIS) Outpaces in Q3; Roth Affirms 'Buy' Rating Ahead of ASH
-
TG Therapeutics' (TGTX) Q3 Results Solid; Roth Remains Positive into ASH Conference
-
ROTH Capital Partners Honored by Global M&A Network
-
Roth Capital Cuts Price Target on Cytori Therapeutics (CYTX) Following 3Q15
-
Cytokinetics (CYTK) and Amgen Inc. (AMGN) Announce COSMIC-HF Data; Roth Capital Raises Price Target to $22
-
RedHill Biopharma Reports Results for the Third Quarter of 2015
-
First Data from Rexahn's (RNN) Archexin Phase 2a Release; Appears Right on Track - Roth
-
Vascular Biogenics Ltd. Announces Closing of $15 Million Underwritten Offering of Ordinary Shares and Warrants
-
Pixelworks to Participate at ROTH Technology Corporate Access Day on November 18
-
Adesto Technologies to Participate at ROTH New York Technology Corporate Access Day on November 18
-
Skullcandy's (SKUL) Higher-Than-Expected Gross Margin Offset Low Revenue; Roth Capital Reiterates Buy
-
Sarepta (SRPT) Conditional-Approval Thesis Unchanged, Roth Capital Says
-
Roth Capital Starts Dimension Therapeutics (DMTX) at Buy
-
Roth Capital Downgrades Constant Contact (CTCT) to Sell Amid Pending Takeover
-
Intec Pharma Reports Results for the Third Quarter of 2015
-
bluebird bio (BLUE) LentiGlobin is Here To Stay, Roth Capital Says; PT Cut to $165
-
Streetinsider.com's Hot Lunchtime Reads 11/5: (VRX) (CAB) (QCOM) (BLRX) (RNWK)
-
BioLineRx's (BLRX) Latest BL-8040 Phase 2 Data in r/r AML is 'Intriguing' - Roth Capital
-
Pre-Open Stock Movers 11/05: (AWAY) (SD) (FB) Higher; (XENT) (LCI) (BLUE) Lower (more...)
-
Roth Capital Downgrades Energy Focus (EFOI) to Neutral
-
Roth Capital Downgrades Sapiens International Corp. NV (SPNS) to Neutral
-
Roth Capital Upgrades Cogentix Medical (CGNT) to Buy
-
Gerhard Erdelji Joins HomeStreet to Lead Investor Relations
-
Roth Capital Raises Price Target on MaxLinear (MXL) Following 3Q Results
-
Same-Store Sales Remain Strong; Roth Capital Remains Neutral on Denny's Corp (DENN)
-
ROTH Capital Partners to Host Technology Corporate Access Day in New York City, NY on November 18th, 2015
-
Top Image Systems to Participate in the ROTH Technology Corporate Access Day in New York
-
Better Than Anticipated Cash Costs Drive EPS Beat for Coeur Mining (CDE); Roth Capital Reiterates Buy
-
Non-Core Brands Downside Contribute to ANI Pharma's (ANIP) Revenue Miss; Roth Capital Reiterates Buy
-
MeetMe (MEET) PT Bumped to $4.25 at Roth Capital Post Q3
-
Roth Capital Downgrades Enphase Energy (ENPH) to Neutral
-
Roth Affirms Rexahn Pharma (RNN) at 'Buy'; Broad POC Program Initiation, Archexin Data in mRCC on Tap
-
VBL Therapeutics (VBLT) Prices $15M Offering of Ordinary Shares and Warrants
-
Vascular Biogenics Ltd. Announces Pricing of $15 Million Underwritten Offering of Ordinary Shares and Warrants
-
Vascular Biogenics Ltd. Announces Pricing of $15 Million Underwritten Offering of Ordinary Shares and Warrants
-
Roth Capital Cuts Price Target on Constant Contact (CTCT) Following Announced Acquisition by Endurance International Group (EIGI)
-
Notable 52-Week Highs and Lows 11/2:(MGM) (GT) (NEO) High; (EIGI) (TKAI) (ENPH) Low
-
Roth Capital Expects In-Line Results From SolarEdge Technologies (SEDG) 1Q16
-
Roth Capital Cuts Price Target on Enphase Energy (ENPH) Ahead of 3Q Earnings Report
-
Escalade (ESCA) Reports 3Q EPS Miss; Roth Capital Reiterates Buy
-
Exact Sciences (EXAS) Releases Light 4Q Guidance; Roth Capital Cuts Price Target to $12
-
SolarCity's (SCTY) Kitchen Sink Quarter – Roth Capital
-
Roth Capital Upgrades GP Strategies (GPX) to Buy
-
OCTANe Set to Host 10th Annual Medical Device & Investor Forum
-
Notable Analyst Rating Changes 10/29: (LNCE) (MPEL) (PEGI) Upgraded; (RL) (DG) (ROK) Downgraded
-
Roth Capital Reiterates Buy on Ellie Mae (ELLI) Following 3Q Results

